New publication! Comparing Strategies to Introduce Two New Antibiotics for Gonorrhea: A Modeling Study featuring authors: @mckline98.bsky.social, @kroster.bsky.social, @dhelekal.bsky.social, @rumpl-er.bsky.social, and @yhgrad.bsky.social. Read it here at bit.ly/3Z1Zplh
U.S. gonorrhea rates fell in 2022 and 2023 after nearly a decade of increases—new paper by @kroster.bsky.social and @yhgrad.bsky.social maps out possible drivers, current evidence, and the data needed to understand what is causing the decline. Read more at bit.ly/4aWmc9i
⚠️ New preprint ⚠️: Two new antibiotics are likely coming for gonorrhea 💊. How should we deploy them in the US to minimize drug resistance? @kroster.bsky.social @dhelekal.bsky.social Eva Rumpler @yhgrad.bsky.social [1/10]
www.medrxiv.org/content/10.1...
Thanks to @YHGrad and Peter White for the supervision and collaboration!
A critical point: CDC data defined the trends and lay the foundation to guide and optimize interventions. We need continued and expanded public health efforts, not cuts, else we risk losing these gains in health.
We outline next steps in research, data collection, and surveillance to address each of these possible factors.
We review possible drivers and their expected impact on gonorrhea, chlamydia, and syphilis:
🧪 Changes in screening, reporting, & diagnostic accuracy
👥 Impact of COVID-19 & mpox on sexual behavior
💉 Protection through vaccination with Bexsero
💊 Doxy-PEP
📋 Changes in antibiotic treatment guidelines
New preprint. After years of increases, gonorrhea diagnosis rates dropped in the US in 2022 and 2023. While the news is promising, understanding WHY is key to sustaining progress.
dash.harvard.edu/handle/1/427...
In our new paper in PLOS Neglected Tropical Diseases, we quantified the gap between expected and observed dengue cases in Brazil. We used an interrupted time series approach, incorporating predictions generated by machine learning models. With @kroster.bsky.social
journals.plos.org/plosntds/art...
Now published in AJE: academic.oup.com/aje/advance-...
Thank you to all our colleagues at MDPH, CDC, Stanford, and HSPH for the support on this project! yhgrad.bsky.social mintturonn.bsky.social jsalomon.bsky.social as well as Heather Elder, Kathy Hsu, Kathleen Roosevelt (MDPH), and Tom Gift (CDC), not (yet) on Bluesky.
Scaling up surveillance is costly – our model helps improve interpretation of existing data by estimating the infection landscapes that could underlie what we observe through surveillance.
If we stop detecting new cases, how long must we wait before we can be confident that there is no ongoing transmission? The likelihood of strain elimination rose from only 34% when the strain was first detected to 98% after 6 months without detected cases.
When a strain is first identified, we estimated that an additional 5.4 cases would be undetected; but the estimate dropped to 2.5 undetected cases with no new infections reported over the next 180 days.
In scenarios with two initial detected cases, our simulations varied from quick elimination to persistence, highlighting the challenges facing public health agencies as they weigh how to respond.
We worked to address this question using a stochastic model, in collaboration with the Massachusetts Department of Public Health, as the first strains in the US with reduced susceptibility to all approved antibiotics were detected here in MA in 2022. www.thelancet.com/journals/lan...
New preprint: Drug resistant gonorrhea is a big public health problem. Resistance to ceftriaxone, the last approved antibiotic, is spreading globally. When we first detect one of these very resistant isolates, how many undetected cases are there likely to be? www.medrxiv.org/content/10.1...
